

Curriculum Vitae

Personal information **Jan Mol**

Work experience

1. Employer: Utrecht University
 - Start date: 111984
 - End date: 082020
 - Position: Associate Professor
 - Activities: Jan Mol is project leader of the program on Comparative and Translational Oncology which is part of the Tissue Repair program of the faculty of Veterinary Medicine of Utrecht University. He is responsible for the scientific and laboratory part of the oncology program. The projects are focused around the role of cancer stem cells in mammary gland, adrenal gland, and insulinomas. The laboratory has ample expertise in gene expression studies (microarray, qRT_PCR), cell culture (transfection, reporter assays, organoid culture), FACS analysis and protein chemistry (IHC, Wblot). His special interest is the role of progesterone in the pathogenesis of mammary cancer and in mammary cancer stem cell differentiation. Hallmarks are the discovery of the local mammary expression of growth hormone (GH) and IGF_I, expression analysis of mammary genes using microarray analysis, the unique role of the canine progesterone receptor_B and the role of Wnt signalling in mammary carcinogenesis. Jan Mol is (co)author of over 185 peer-reviewed publications, and guided 20 PhD studies.
 - Country: Netherlands

Education and training

1. Subject: Erasmus University Rotterdam
 - Start date: 041981
 - End date: 041984
 - Qualification: PhD
 - Organization: Ph.D. thesis: The deiodination of thyroid hormone in rat liver
 - Country: Netherlands

Additional information

Publications

See <https://orcid.org/0000-0002-0843-8088>

Selected publications: Buishand FO, Arkesteijn GJ, Feenstra LR, Oorsprong CW, Mestemaker M, Starke A, Speel EJ, Kirpensteijn J, Mol JA. Identification of CD90 as putative cancer stem cell marker and therapeutic target in insulinomas. *Stem Cells Dev.* 2016;25(11):826-835. Capodanno, Ylenia, Buishand, Floryne O, Pang, Lisa Y, Kirpensteijn, Jolle, Mol, Jan A & Argyle, David J (2018). Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells. *Endocrine-Related Cancer*, 25, (pp. 131-144). Gracanian A, Voorwald FA, van Wolferen M, Timmermans_Sprang E, Mol JA. Marginal activity of progesterone receptor B (PR_B) in dogs but high incidence of mammary cancer. *J Steroid Biochem Mol Biol.* 2014;144:492-499. Gracanian A, Timmermans_Sprang EP, van Wolferen ME, Rao NA, Grizelj J, Vince S, Hellmen E, Mol JA. Ligand-independent canonical Wnt activity in canine mammary tumor cell lines associated with aberrant LEF1 expression. *PLoS One.* 2014;9(6):e98698. Gracanian A, van Wolferen ME, Sartorius CA, Brenkman AB, Schoonen WG, Mol JA. Canid progesterone receptors lack activation function 3 domain-dependent activity. *Endocrinology* 153: 6104-6113, 2012. Mauchle U, Selvarajah GT, Mol JA, Kirpensteijn J, Verheije MH. Identification of anti-proliferative kinase inhibitors as potential therapeutic agents to treat canine osteosarcoma. *Vet J.* 2015;205(2):281-287. Sanders, Karin, de Wit, Wesley L, Mol, Jan A, Kurlbaum, Max, Kendl, Sabine, Kroiss, Matthias, Kooistra, Hans S & Galac, Sara (2018). Abiraterone Acetate for Cushing's Syndrome _ Study in a Canine Primary Adrenocortical Cell Culture Model. *Endocrinology*, 159 (11), (pp. 3689-3698). Timmermans_Sprang, Elpetra P M, Gracanian, Ana & Mol, Jan A (2017). Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans _ New Treatment Target Identification. *Frontiers in Veterinary Science*, 4 (13 p.). Timmermans_Sprang EP, Gracanian A, Mol JA. High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression. *BMC Cancer* 2015;15:545 Zandvliet M, Teske E, Schrickx JA, Mol JA. A longitudinal study of ABC transporter expression in canine multicentric lymphoma. *Vet J.* 2015;205(2):263-271.

Projects

Patient advocacy work:

Editorial board of the 5th edition of the WHO Classification of Haematolymphoid Tumours

Advisory board KWF (Dutch Cancer Society)

Supervisory board Stichting Hematon (Organization for patients with blood cancer)

Member Demonstrator Advisory Board of Oncode Accelerator

Research projects:

GHR depletion to cure cancer

Crosstalk of Wnt and GH signaling in breast cancer
Identification of cell populations with stem cell characteristics in the insulinoma
Pathogenesis and Medical Treatment of Canine Cortisol_Secreting Adrenocortical Tumors

Memberships

Member of the editorial board of Domestic Animal Endocrinology. Member of the scientific committee of COST action in the field of 'Mammary Gland Biology' (1996_2006). Board member Dutch Patient Organization Hematon (Patients with leukemia, lymphoma or stem cell transplantation). Advisory board KWF (Dutch Cancer Society). Member of the Demonstrator Advisory Board of Oncode Accelerator.

Other Relevant Information

I am a patient representative